Literature DB >> 2527223

Pharmacokinetics of teicoplanin in subjects with varying degrees of renal function.

N Derbyshire1, D B Webb, D Roberts, D Glew, J D Williams.   

Abstract

The pharmacokinetics of teicoplanin were studied in 20 subjects with varying degrees of renal function after administration of a single 200 mg intravenous dose. Pharmacokinetic parameters were calculated with a three compartment open model and by non-compartmental analysis. The elimination half-life increased as creatinine clearance decreased (rs = -0.87, P less than 0.001). The distribution volume was 1.0 (+/- 0.3) 1/kg of actual body weight and did not vary with changes in creatinine clearance. In normal subjects the main route of elimination was renal. The plasma clearance of teicoplanin correlated with creatinine clearance (rs = 0.91, P less than 0.001). At lower levels of creatinine clearance the variation in elimination half-life was such that we recommend individualization of the teicoplanin dosage following the measurement of the drug concentration in plasma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527223     DOI: 10.1093/jac/23.6.869

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

2.  Suboptimal antimicrobial drug exposure in patients with renal impairment.

Authors:  David Czock; Martino Spitaletta; Frieder Keller
Journal:  Int J Clin Pharm       Date:  2015-05-28

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of teicoplanin.

Authors:  M Rowland
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

Review 5.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 6.  Anti-infective treatment in intensive care: the role of glycopeptides.

Authors:  R N Grüneberg; A P Wilson
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

7.  Population pharmacokinetics of teicoplanin in patients with endocarditis.

Authors:  D K Yu; E Nordbrock; S J Hutcheson; E W Lewis; W Sullivan; V O Bhargava; S J Weir
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

Review 8.  Use of teicoplanin in community medicine.

Authors:  A P Wilson; R N Grüneberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-09       Impact factor: 3.267

9.  Therapeutic Drug Level Monitoring of Teicoplanin in Korean Pediatric Patients with Normal versus Impaired Renal Function.

Authors:  Joon Sik Choi; Jong Min Kim; Dongsub Kim; Si Ho Kim; Heeyeon Cho; Hyung Doo Park; Soo Youn Lee; Cheol In Kang; Yae Jean Kim
Journal:  J Korean Med Sci       Date:  2020-11-30       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.